Meridian Bioscience, Inc. (NASDAQ:VIVO) saw unusually-strong trading volume on Thursday . Approximately 293,850 shares changed hands during trading, an increase of 40% from the previous session’s volume of 209,683 shares.The stock last traded at $19.38 and had previously closed at $19.43.

A number of analysts have recently issued reports on VIVO shares. Canaccord Genuity reissued a “hold” rating and set a $20.00 target price on shares of Meridian Bioscience in a research note on Monday, August 1st. Hilliard Lyons lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Finally, Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. Meridian Bioscience has an average rating of “Hold” and a consensus target price of $21.25.

The firm has a 50 day moving average price of $19.71 and a 200-day moving average price of $19.79. The firm has a market capitalization of $820.02 million and a P/E ratio of 23.20.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by $0.01. The business earned $50.70 million during the quarter, compared to the consensus estimate of $52.85 million. During the same quarter in the prior year, the firm earned $0.22 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts anticipate that Meridian Bioscience, Inc. will post $0.86 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 18th. Shareholders of record on Monday, August 8th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 4th. This represents a $0.80 dividend on an annualized basis and a yield of 4.10%.

An institutional investor recently raised its position in Meridian Bioscience stock. Rhumbline Advisers increased its position in Meridian Bioscience, Inc. (NASDAQ:VIVO) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 117,674 shares of the company’s stock after buying an additional 4,925 shares during the period. Rhumbline Advisers owned 0.28% of Meridian Bioscience worth $2,415,000 as of its most recent filing with the SEC.

Meridian Bioscience, Inc (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.